论文部分内容阅读
Dale氏首先提出肾上腺素能受体的分类,并指出麦角制剂能消除肾上腺素或交感神经性兴奋运动效应。Ahlquist氏随后把肾上腺素素能受体再分为α与β两型,Ahlquist的分类曾用不同药物产生对α和β受体选择性阻滞的研究得到支持。第一种成份发现为双氯异丙肾上腺素(Dichloroisoprenaline)、认为特别对B-肾上腺素能有阻滞作用,它能拮抗交感神经兴奋时,心肌肌力和频率作用(ChronotroPicAction)及其异丙肾上腺素周围血管扩张作用。但不能阻滞α-肾上腺素能受体有关的反
Dale first proposed the classification of adrenergic receptors, and pointed out that ergot preparations can eliminate the effect of adrenaline or sympathetic motor activity. Ahlquist then subdivided adrenergic receptors into alpha and beta forms, and the Ahlquist classification has been supported by studies with different drugs that produce selective blockade of the alpha and beta receptors. The first ingredient found to be Dichloroisoprenaline, which is thought to block B-adrenergic activity in particular, counteracts the effects of ChronotroPicAction and its isoprene on sympathetic activity, Adrenergic peripheral vasodilatation. But can not block the α-adrenergic receptor-related anti